Researchers
Advance your Alzheimer’s Disease Research with pTau217
Researchers worldwide are advancing AD research with ALZpath’s pTau217 antibody – a trusted reagent delivering sensitive, reliable detection across studies and collaborators.
ALZpath has developed a highly specific monoclonal antibody against phosphorylated tau at threonine 217 (pTau217). In immunoassays, that antibody functions as the capture antibody in a sandwich format [1]. This makes it ideally suited for ultra-sensitive detection of pTau217 in plasma and CSF.
The ALZpath antibody is licensed across multiple assay platforms, enabling broad translational and research access.
Note: ALZpath’s pTau217 antibody is a Research Use Only (RUO) reagent.
pTau217 Antibody Licensed Across Multiple Assay Platforms
Partner | Platform (example) | Status |
|---|---|---|
Beckman Coulter Diagnostics | Immunoassay platform (DxI series) | RUO (IVD in development) |
Roche Diagnostics | Elecsys® immunoassay platform | RUO (IVD in development) |
Alamar Biosciences | NULISA™ ultra-sensitive proteomics platform
| RUO |
Bio-Techne | Ella™ / Simple Plex™ immunoassay platform
| RUO |
Quanterix | Simoa® HD-X (and SR-X) immunoassay platform | RUO |
RUO = Research Use Only
IVD = In Vitro Diagnostic (IVD tests must undergo FDA submission and approval before they can be made available)
Commitment to Scientific Excellence
ALZpath is committed to advancing Alzheimer’s disease research through open science and peer-reviewed publications.
- Longitudinal studies monitoring disease progression and conversion from presymptomatic to MCI to AD.
- Head-to-head comparisons confirming assay accuracy versus other leading tests
- Analytical Validation which focuses on assay precision and reproducibility
Visit our full list of studies utilizing ALZpath pTau217 on our Publications Page.
See the Evidence
ALZpathDx meets the performance standards recommended by the Global CEO Initiative on Alzheimer’s Disease (CEOi) blood biomarker working group as a confirmatory blood test that is equivalent to cerebrospinal fluid assays and amyloid PET imaging. See the evidence by visiting the CEOi website.
Collaboration Opportunities
ALZpath welcomes collaboration with researchers, clinical trial groups, and diagnostic developers to advance biomarker science and accelerate translation into clinical use.
Opportunities include:
- Co-development of new assays.
- Partnerships in clinical trials as exploratory or secondary endpoints.
- Licensing of the ALZpath antibody for research and clinical use.
Collaborations and Consortia
Access the ALZpath pTau217 Antibody
The ALZpath pTau217 antibody is available for research use, evaluation, and assay development. If you’re interested in using the antibody in your own studies or platforms, you can reach out to us directly.
"*" indicates required fields
Important Note: Our diagnostic partners are actively using the ALZpath antibody to develop their pTau217 assays. These assays are Research Use Only (RUO) at this stage, with clinical availability expected to expand.
Researchers FAQs
How do I access the RUO version of the pTau217 test?
Researchers diagnostic companies and drug developers can contact us by filling out this form.
The RUO (Research Use Only) version of the test can be accessed by ordering through our partners by filling out the form above.
What is the sensitivity/specificity of this test?
The pTau217 test has a PPV/NPV of 95% depending on the cut-off. Amyloid AUC: 0.957, Tau AUC: 0.952.
Still have Questions?
Reach Out to Learn More
Get in touch to learn more about ALZpath’s research collaborations and antibody access.